Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4888-4894

  Nishimura, Kazuo ^b   Ting, Huei Ju ^a   Harada, Yasunori ^b   Tokizane, Takashi ^b   Nonomura, Norio ^b   Kang, Hong Yo ^a   Chang, Hong Chiang ^a   Yeh, Shuyuan ^a   Miyamoto, Hiroshi ^a   Shin, Masaru ^b   Aozasa, Katsuyuki ^b   Okuyama, Akihiko ^b   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; GELSOLIN; HYDROXYFLUTAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; TRANSACTIVATION; XENOGRAFT;

ANIMALS; CLONING, MOLECULAR; COS CELLS; DIHYDROTESTOSTERONE; FLUTAMIDE; GELSOLIN; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANS-ACTIVATION (GENETICS);

EID: 0042440803     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Chang, C., Saltzman, A., Yeh, S., Young, W., Keller, E., Lee, H. J., Wang, C., and Mizokami, A. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr., 5: 97-125, 1995.
2. Hughes, I. A. Minireview: sex differentiation. Endocrinology, 142: 3281-3287, 2001.
3. Yong, E. L., Lim, J., Qi, W., Ong, V., and Mifsud, A. Molecular basis of androgen receptor diseases. Ann. Med., 32: 15-22, 2000.
4. Hsiao, P. W., and Chang, C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J. Biol. Chem., 274: 22373-22379, 1999.
5. Kang, H. Y., Yeh, S., Fujimoto, N., and Chang, C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J. Biol. Chem., 274: 8570-8576, 1999.
6. Fujimoto, N., Yeh, S., Kang, H. Y., Inui, S., Chang, H. C., Mizokami, A., and Chang, C. Cloning and characterization of androgen receptor coactivator. ARA55, in human prostate. J. Biol. Chem., 274: 8316-8321, 1999.
7. Yeh, S., and Chang, C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. USA, 93: 5517-5521, 1996.
8. Hsiao, P. W., Lin, D. L., Nakao, R., and Chang, C. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem., 274: 20229-20234, 1999.
9. Wang, X., Yeh, S., Wu, G., Hsu, C. L., Wang, L., Chiang, T., Yang, Y., Guo, Y., and Chang, C. Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J. Biol. Chem., 276: 40417-40423, 2001.
10. Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., Hsiao, P., Wang, C., Su, C., and Chang, C. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem. Biophys. Res. Commun., 248: 361-367, 1998.
11. Ding, X. F., Anderson, C. M., Ma, H., Hong, H., Uht, R. M., Kushner, P. J., and Stallcup, M. R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol., 12: 302-313, 1998.
12. Berrevoets, C. A., Doesburg, P., Steketee, K., Trapman, J., and Brinkmann, A. O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol., 12: 1172-1183, 1998.
13. Tan, J. A., Hall, S. H., Petrusz, P., and French, F. S. Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator. Endocrinology, 141: 3440-3450, 2000.
14. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics. CA Cancer J. Clin., 45: 8-30, 1995.
15. Prins, G. S., Sklarew, R. J., and Pertschuk, L. P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol., 159: 641-649, 1998.
16. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
17. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Jr., Bueschen, A. J., and Lowe, B. A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med., 339: 1036-1042, 1998.
18. Kelly, W. K., Slovin, S., and Scher, H. I. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol. Clin. North Am., 24: 421-431, 1997.
19. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
20. Dreicer, R. The evolving role of hormone therapy in advanced prostate cancer. Cleve. Clin. J. Med., 67: 725-726, 2000.
21. Hakimi, J. M., Rondinelli, R. H., Schoenberg, M. P., and Barrack, E. R. Androgen-receptor gene structure and function in prostate cancer. World J. Urol., 14: 329-337, 1996.
22. Magi-Galluzzi, C., Xu, X., Hlatky, L., Hahnfeldt, P., Kaplan, I., Hsiao, P., Chang, C., and Loda, M. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod. Pathol., 10: 839-845, 1997.
23. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang, C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 96: 5458-5463, 1999.
24. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Bubley, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383-1388, 1997.
25. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
26. Yeh, S., Kang, H. Y., Miyamoto, H., Nishimura, K., Chang, H. C., Ting, H. J., Rahman, M., Lin, H. K., Fujimoto, N., Hu, Y. C., Mizokami, A., Huang, K. E., and Chang, C. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine, 11: 195-202, 1999.
27. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., and Wilson, E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res., 61: 4315-4319, 2001.
28. Kwiatkowski, D. J. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr. Opin. Cell Biol., 11: 103-108, 1999.
29. Sun, H. Q., Yamamoto, M., Mejillano, M., and Yin, H. L. Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem., 274: 33179-33182, 1999.
30. Fujita, H., Allen, P. G., Janmey, P. A., Azuma, T., Kwiatkowski, D. J., Stossel, T. P., and Kuzumaki, N. Induction of apoptosis by gelsolin truncates. Ann. N. Y. Acad. Sci., 886: 217-220, 1999.
31. Koya, R. C., Fujita, H., Shimizu, S., Ohtsu, M., Takimoto, M., Tsujimoto, Y., and Kuzumaki, N. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J. Biol. Chem., 275: 15343-15349, 2000.
32. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
33. Lee, H. K., Driscoll, D., Asch, H., Asch, B., and Zhang, P. J. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate, 40: 14-19, 1999.
34. Guan, K. L., and Dixon, J. E. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem., 192: 262-267, 1991.
35. Ting, H. J., Yeh, S., Nishimura, K., and Chang, C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc. Natl. Acad. Sci. USA, 99: 661-666, 2002.
36. Yuan, S., Trachtenberg, J., Mills, G. B., Brown, T. J., Xu, F., and Keating, A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res., 53: 1304-1311, 1993.
37. McDonald, S., Brive, L., Agus, D. B., Scher, H. I., and Ely, K. R. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res., 60: 2317-2322, 2000.
38. Ozanne, D. M., Brady, M. E., Cook, S., Gaughan, L., Neal, D. E., and Robson, C. N. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol. Endocrinol., 14: 1618-1626, 2000.
39. Prendergast, G. C., and Ziff, E. B. Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. EMBO J., 10: 757-766, 1991.
40. Wulfkuhle, J. D., Donina, I. E., Stark, N. H., Pope, R. K., Pestonjamasp, K. N., Niswonger, M. L., and Luna, E. J. Domain analysis of supervillin, an F-actin bundling plasma membrane protein with functional nuclear localization signals. J. Cell Sci., 112: 2125-2136, 1999.
41. Salazar, R., Bell, S. E., and Davis, G. E. Coordinate induction of the actin cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated phosphoprotein, and profilin during capillary morphogenesis in vitro. Exp. Cell Res., 249: 22-32, 1999.
42. Asch, H. L., Head, K., Dong, Y., Natoli, F., Winston, J. S., Connolly, J. L., and Asch, B. B. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res., 56: 4841-4845, 1996.
43. Dosaka-Akita, H., Hommura, F., Fujita, H., Kinoshita, I., Nishi, M., Morikawa, T., Katoh, H., Kawakami, Y., and Kuzumaki, N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res., 58: 322-327, 1998.
44. Tanaka, M., Mullauer, L., Ogiso, Y., Fujita, H., Moriya, S., Furuuchi, K., Harabayashi, T., Shinohara, N., Koyanagi, T., and Kuzumaki, N. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res., 55: 3228-3232, 1995.
45. Shieh, D. B., Godleski, J., Herndon, J. E., 2nd, Azuma, T., Mercer, H., Sugarbaker, D. J., and Kwiatkowski, D. J. Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer (Phila.), 85: 47-57, 1999.
46. Onda, H., Lueck, A., Marks, P. W., Warren, H. B., and Kwiatkowski, D. J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Investig., 104: 687-695, 1999.